News
RXRX
3.590
+1.13%
0.040
Why Recursion Pharmaceuticals Bears Were Right Before The Drop
Simply Wall St · 11h ago
Morgan Stanley's list of AI adoption leaders
Seeking Alpha · 2d ago
Weekly Report: what happened at RXRX last week (1102-1106)?
Weekly Report · 2d ago
Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation
Simply Wall St · 2d ago
Recursion Stock Gets A Lift From Trial Progress And New Board Chair
Simply Wall St · 5d ago
Why Does Recursion Pharmaceuticals (RXRX) New Phase 2 Data And Chair Appointment Matter?
Simply Wall St · 6d ago
Bank of America Securities Remains a Hold on Recursion Pharmaceuticals (RXRX)
TipRanks · 11/04 13:52
Recursion Pharmaceuticals (RXRX) Stock Faces Q3 Results Cash Burn Question
Simply Wall St · 11/03 23:40
Recursion (RXRX) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/03 20:47
Most and least shorted mid- to mega-cap healthcare stocks at the end of October
Seeking Alpha · 11/03 15:00
Most shorted stocks on Wall Street
Seeking Alpha · 11/03 14:55
Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances Pipeline
NASDAQ · 11/03 07:13
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/02 23:10
Recursion Pharmaceuticals: Q3 Earnings Snapshot
Barchart · 11/02 22:37
Recursion Reports Clinical Progress as Sanofi Options First Candidate
TipRanks · 11/02 22:24
Recursion Pharmaceuticals reports Q3 EPS (22c), consensus (23c)
TipRanks · 11/02 21:50
Recursion reports Phase 2 REC-4881 data in inherited polyp disorder
TipRanks · 11/02 21:50
Recursion appoints former Schering-Plough CEO Fred Hassan as chair
TipRanks · 11/02 21:50
Recursion Pharmaceuticals GAAP EPS of -$0.22 misses by $0.01, revenue of $18.55M beats by $3.74M
Seeking Alpha · 11/02 21:35
Recursion Appoints Fred Hassan As Board Chair, Effective Oct. 31
Benzinga · 11/02 21:13
More
Webull provides a variety of real-time RXRX stock news. You can receive the latest news about Recursion Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.